% IMPORTANT: The following is UTF-8 encoded. This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.
@ARTICLE{Kim:154376,
author = {J. Kim and J. R. Park and J. Choi and I. Park and Y. Hwang
and H. Bae and Y. Kim and W. Choi and J. M. Yang and S. Han
and T.-Y. Chung and P. Kim and Y. Kubota and H. Augustin$^*$
and W.-Y. Oh and G. Y. Koh},
title = {{T}ie2 activation promotes choriocapillary regeneration for
alleviating neovascular age-related macular degeneration.},
journal = {Science advances},
volume = {5},
number = {2},
issn = {2375-2548},
address = {Washington, DC [u.a.]},
publisher = {Assoc.},
reportid = {DKFZ-2020-00716},
pages = {eaau6732 -},
year = {2019},
note = {DKFZ-ZMBH Alliance},
abstract = {Choriocapillary loss is a major cause of neovascular
age-related macular degeneration (NV-AMD). Although vascular
endothelial growth factor (VEGF) blockade for NV-AMD has
shown beneficial outcomes, unmet medical needs for patients
refractory or tachyphylactic to anti-VEGF therapy exist. In
addition, the treatment could exacerbate choriocapillary
rarefaction, necessitating advanced treatment for
fundamental recovery from NV-AMD. In this study, Tie2
activation by angiopoietin-2-binding and Tie2-activating
antibody (ABTAA) presents a therapeutic strategy for NV-AMD.
Conditional Tie2 deletion impeded choriocapillary
maintenance, rendering eyes susceptible to NV-AMD
development. Moreover, in a NV-AMD mouse model, ABTAA not
only suppressed choroidal neovascularization (CNV) and
vascular leakage but also regenerated the choriocapillaris
and relieved hypoxia. Conversely, VEGF blockade degenerated
the choriocapillaris and exacerbated hypoxia, although it
suppressed CNV and vascular leakage. Together, we establish
that angiopoietin-Tie2 signaling is critical for
choriocapillary maintenance and that ABTAA represents an
alternative, combinative therapeutic strategy for NV-AMD by
alleviating anti-VEGF adverse effects.},
keywords = {Angiopoietin-1 (NLM Chemicals) / Angpt1 protein, mouse (NLM
Chemicals) / Vascular Endothelial Growth Factor A (NLM
Chemicals) / Receptor, TIE-2 (NLM Chemicals) / Tek protein,
mouse (NLM Chemicals)},
cin = {A190},
ddc = {500},
cid = {I:(DE-He78)A190-20160331},
pnm = {311 - Signalling pathways, cell and tumor biology
(POF3-311)},
pid = {G:(DE-HGF)POF3-311},
typ = {PUB:(DE-HGF)16},
pubmed = {pmid:30788433},
pmc = {pmc:PMC6374104},
doi = {10.1126/sciadv.aau6732},
url = {https://inrepo02.dkfz.de/record/154376},
}